Isle of Wight eFormulary






Please note the E-Formulary pages are currently under review and the content has not been updated since November 2017.
For any questions regarding formulary prescribing options please call 01983 822099 ext. 5469.


Please click the relevant links to the left to access the BNF section of choice.

The Island electronic Formulary is a limited list of medicines available for prescribing in both primary and secondary care. The formulary seeks to promote the use of the most cost effective drugs in each class as assessed by the Drugs Advisory Committee, a representative body made up of local clinicians, pharmacists, nurses and finance managers across the health economy. The formulary is mainly applicable to the adult setting, since many medicines used in the paediatric setting are used in an “off label” fashion. This situation does not however, exclude the paediatric environment from conforming to the general principles surrounding the system for the managed entry of new drugs onto the island formulary. Entry into the formulary will primarily depend on considerations of safety and efficacy in comparison with established treatments. Value for money will also be taken into account, particularly when safety and efficacy differences are marginal, and the impact on GP prescribing is significant. Funding considerations will also be an issue, particularly where new drugs have significant revenue consequences.

The Aims of the Island Formulary are:

To provide a comprehensive, approved range of drugs for use in the hospital - allows a new prescriber to indentify which drugs are available for prescribing within the trust.

To avoid cost and confusion caused by stocking an unnecessarily wide range of drugs - allows reduced stock holding in Pharmacy resulting in efficient space utilisation both in Pharmacy and on wards.

To promote safe, effective and economic prescribing - local specialist advice on best drugs in class; acts as valuable training for juniors.

Well managed introduction of new drugs following NICE TA guidelines.

Prescribers and pharmacists more familiar with fewer products handle them better.

When a new product becomes available, it will inevitably claim to be better than its competitors. Experience has shown us that this is not always true, and that additionally, a number of significant side effects may only become apparent following wider usage. The true place in therapy of a new agent is rarely immediately apparent. For these reasons, we would not normally seek to add a product to the formulary immediately following marketing (unless significant rationale is available). Continued monitoring of the literature will be carried out whilst considering the place in the formulary. The formulary is up-dated regularly and so paper copies are not routinely circulated. A robust system is in place to implement & monitor the uptake of NICE-approved drug therapies.

As part of the business planning and budget setting process for each new financial year, senior prescribers are consulted as part of an “horizon scanning” exercise. The projected new drug needs, and the likely financial implications are drawn together each year by the Pharmacy department, and this report forms the basis for the drugs budget.

Where a drug has been subject to a positive NICE appraisal, it is assumed that the prescribing guidance of this agent will be automatic within the Trust and the relevant specialist(s) are responsible for the introduction and adherence to guidance. If a NICE-approved drug intervention is not to be prescribed, a clear exception report needs to be documented by the prescriber to corroborate why that clinical decision was reached.

Shared Care Agreements (SCA)

Children ADHD

ADHD in Children 

Adult ADHD

Atomoxetine, Dexamfetamine, Methylphenidate


Drugs Advisory Committee

Formulary New Drug Application Form 

DAC Minutes

Unlicensed Medicines

Liability form for unlicensed and off license medicines

Individual Funding Requests (IFR)

Please use the CCG IFR form, except in circumstances that are covered by specialist commissioning when the NHSE IFR form should be used.  NHSE policies can be found here.

Formulary Management

Clinical Pathway for Drugs

Dressings Formulary

Cancer Drugs Fund (CDF) - Drugs List

Drug Classifications

Red - for consultant initiation and continuation only.

Amber - for consultant initiation and GP continuation in line with an approved shared care agreement. This applies to products which require specialist initiation and possibly early monitoring, but which can be managed on an ongoing basis by a GP who is sufficiently informed about the product to manage the patient effectively.

Yellow - does not require a shared care agreement between consultant and GP, but should only be started on the advice of a specialist.

Green - for initiation and continuation by any prescriber who wishes to use the product. NB - a product on the green list is not automatically implied to be a first-line choice for a particular condition, only an approved option.


For any eFormulary comments, reporting broken links etc, please email

Keep up to date with the latest news

Find out what is happening in our services here.

Tell Us Your Views

Click here to find out how you can feedback to us about your experiences, along with how to raise any concerns, complaints or questions.